• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abbott’s Q2 sales, earnings top forecasts

Abbott’s Q2 sales, earnings top forecasts

July 20, 2017 By Brad Perriello

Abbott logoAbbott (NYSE:ABT) beat expectations today with its second-quarter earnings despite a -84% bottom-line slide.

The Chicago-area healthcare giant posted profits of $283 million, or 16¢ per share, on sales of $6.64 billion for the three months ended June 30, for sales growth of 24.5% compared with Q2 2016.

Adjusted to exclude one-time items, earnings per share were 62¢. Analysts on Wall Street were looking for adjusted EPS of 61¢ on sales of $6.63 billion.

“Halfway through the year, we’re on track with all of our key priorities, including the integration of St. Jude and growth contributions from our pipeline,” chairman & CEO Miles White said in prepared remarks. “We’re also raising our full-year guidance range as we continue to target double-digit ongoing EPS growth.”

Abbott said it now expects to post adjusted EPS of $2.43 to $2.53, up from its prior forecast for $2.40 to $2.50 this year.

ABT shares, which closed up 1.4% at $49.43 apiece yesterday, rose further in pre-market trading today to $50 even, a 1.2% gain.

“This showing is sufficient to support the stock, especially given the improvements we expect for the St. Jude business over the next 12 months,” Cowen analyst Joshua Jennings wrote in a note to investors.

Barclays’ Matthew Taylor said the company ought to be able to consistently grow underlying sales in the mid-single-digit range.

“ABT is our Top Pick and we rate the shares Overweight; we see valuation as reasonable and think revenue acceleration over the next several periods could drive shares higher,” Taylor wrote.

Sales in Abbott’s three core divisions – diagnostics, medical devices and branded generic pharmaceuticals – rose on a reported basis in the quarter, with nutritional products business the only laggard.

Sales in medical devices, Abbott’s largest division, surged about 89% to $2.60 billion.

Global nutrition sales slipped -0.6%.

The company’s pediatric business has been under pressure since last year after China imposed new food safety regulations that required manufacturers to re-register baby formulas with the government.

Net profit from continuing operations more than halved to $270 million, or 15¢ per share due to higher costs.

Material from Reuters was used in this report.

Filed Under: MassDevice Earnings Roundup, Wall Street Beat Tagged With: Abbott

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy